A RANDOMIZED PHASE II STUDY OF BEVACIZUMAB (NSC# 704865) AND GEMCITABINE IN COMB

点击翻译按钮获取中文摘要

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. To determine objective response rate, toxicity and progression-free survival rate of advanced pancreatic cancer patients treated with the combination of Gemcitabine, Bevacizumab and Cetuximab or Gemcitabine, Bevacizumab and OSI-774.